Table 3.

The relationship of vitamin D₃ and its epimers to complications in the group of nondiabetic control participants (n = 290).

	1,25(OH)2D3 (ng/dl) median (range)	p value	25(OH)D3 (ng/dl) median (range)	p value	24,25(OH)2D3 (ng/dl) median (IQR)	p value	3epi25(OH)D3 (ng/dl) median (IQR)	p value
Gender
Male	0.048 (0.031–0.069)	0.001	10.68 (6.96–15.78)	<0.001	0.44 (0.26–0.69)	0.007	0.24 (5.17)	0.081
Female	0.036 (0.017–0.059)		6.21 (3.38–10.82)		0.30 (0.17–0.58)		0.12 (7.15)
Hypertension
No	0.047 (0.030–0.070)	0.001	9.11 (5.14–15.18)	0.350	0.39 (0.20–0.68)	0.557	0.17 (5.17)	0.868
Yes	0.032 (0.021–0.047)		7.96 (4.37–13.12)		0.37 (0.23–0.55)		0.19 (7.15)
Dyslipidemia
No	0.047 (0.029–0.068)	0.001	9.40 (5.92–15.74)	<0.001	0.41 (0.20–0.69)	0.015	0.55 (0.26–1.02)	0.148
Yes	0.035 (0.020–0.054)		7.49 (3.62–12.63)		0.33 (0.21–0.54)		0.36 (0.21–0.84)

1,25(OH)₂D₃, 1,25-dihydroxyvitamin D₃; 25(OH)D₃, 25-hydroxyvitamin D₃; 24,25(OH)₂D₃, 24,25-dihydroxyvitamin D_3; IQR, interquartile range.